Meeting
2021 ASCO Annual Meeting
Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.
Authors
Terence M. Hughes
Icahn School of Medicine at Mount Sinai, New York, NY
Terence M. Hughes , Brianna Empringham , Sumit Gupta , Zachary J. Ward , Jennifer Yeh , Anita K. Wagner , Lewis B. Silverman , Lindsay Lindsay Frazier , Avram Denburg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10031)
DOI
10.1200/JCO.2021.39.15_suppl.10031
Abstract #
10031
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
First Author: Luke Maese
Poster
2024 ASCO Annual Meeting
Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy.
First Author: Manraj Singh Sra
Poster
2023 ASCO Quality Care Symposium
Growth factor use in patients with breast cancer treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen: Cost implications in a safety-net system.
First Author: Sarah Kashanian
Poster
2023 ASCO Quality Care Symposium
Heterogeneity in costs of standard-of-care drug regimens within high volume Enhancing Oncology Model disease groups: Implications for performance risk outside of a provider’s control.
First Author: Katherine Baker